Is It Time To Reassess Elevance Health (ELV) After A 26% One-Year Share Price Fall

Simply Wall St.04-09

Wondering if Elevance Health at around US$311 a share still offers value, or if the best entry point has passed? This article walks through the key numbers that matter for you. The stock has returned ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626922175?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/160077-main-header/1756254056160","is_english":true,"pubTime":"2026-04-09 04:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626922175","market":"nz","top_or_hot":-1,"title":"Is It Time To Reassess Elevance Health (ELV) After A 26% One-Year Share Price Fall","media":"Simply Wall St.","content":"<div>\n<p>Wondering if Elevance Health at around US$311 a share still offers value, or if the best entry point has passed? This article walks through the key numbers that matter for you. The stock has returned ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/is-it-time-to-reassess-elevance-health-elv-after-a-26-one-ye\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time To Reassess Elevance Health (ELV) After A 26% One-Year Share Price Fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time To Reassess Elevance Health (ELV) After A 26% One-Year Share Price Fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-09 04:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/is-it-time-to-reassess-elevance-health-elv-after-a-26-one-ye><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wondering if Elevance Health at around US$311 a share still offers value, or if the best entry point has passed? This article walks through the key numbers that matter for you. The stock has returned ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/is-it-time-to-reassess-elevance-health-elv-after-a-26-one-ye\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1280957306.USD","symbol_name":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/is-it-time-to-reassess-elevance-health-elv-after-a-26-one-ye","article_id":"2626922175","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/160077-main-header/1756254056160"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-elv/elevance-health/news/is-it-time-to-reassess-elevance-health-elv-after-a-26-one-ye","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2626922175","pubTimestamp":1775679777,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Wondering if Elevance Health at around US$311 a share still offers value, or if the best entry point has passed? This article walks through the key numbers that matter for you.\nThe stock has returned 6.5% over the last week and 7.7% over the last month, yet it remains 12.0% lower year to date and 26.1% lower over the last year, which sets an interesting backdrop for thinking about risk and value.\nRecent attention on Elevance Health has focused on its position in the US healthcare sector and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","ELV":"Elevance Health","LU2430703178.SGD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (SGDHDG) INC","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","FCF":"第一联邦金融","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","BK4154":"管理型保健护理","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0061474960.USD":"天利环球焦点基金AU Acc","LU0557290698.USD":"施罗德环球可持续增长基金","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1548497426.USD":"安联环球人工智能AT Acc","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","ELV.AU":"ELEVRA LITHIUM LTD","LU0251142724.SGD":"Fidelity America A-SGD","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4585":"ETF&股票定投概念","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H"},"translate_title":"Elevance Health(ELV)股价一年下跌26%后，是时候重新评估它了吗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"FCF":1,"ELV.AU":1.5,"ELV":1.5},"content_text":"Wondering if Elevance Health at around US$311 a share still offers value, or if the best entry point has passed? This article walks through the key numbers that matter for you. The stock has returned 6.5% over the last week and 7.7% over the last month, yet it remains 12.0% lower year to date and 26.1% lower over the last year, which sets an interesting backdrop for thinking about risk and value. Recent attention on Elevance Health has focused on its position in the US healthcare sector and how the market is reassessing companies that combine insurance operations with healthcare services. News flow around regulatory scrutiny of healthcare costs and ongoing debate over reimbursement models has also kept investors focused on whether current prices fairly reflect these risks. Against this backdrop, Elevance Health currently scores a full 6 out of 6 on our valuation checks. The next sections will break down what that means using standard valuation methods, before closing with a more comprehensive way of thinking about value that goes beyond a single model.  Find out why Elevance Health's -26.1% return over the last year is lagging behind its peers. AdvertisementApproach 1: Elevance Health Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and discounting them back to today’s value using a required rate of return. For Elevance Health, the latest twelve month Free Cash Flow (FCF) is about $2.96b. Analysts provide explicit FCF estimates for several years, which are then extended by Simply Wall St’s model. For example, projected FCF is $4.97b in 2026 and $8.29b in 2030, with these and later figures discounted to reflect the fact that money expected in the future is worth less than cash received today. Adding these discounted cash flows together, the DCF model, using a 2 Stage Free Cash Flow to Equity approach, arrives at an estimated intrinsic value of about $1,010 per share. Compared with a current share price of around $311, this implies Elevance Health is about 69.1% undervalued based on this method alone. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Elevance Health is undervalued by 69.1%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks. ELV Discounted Cash Flow as at Apr 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Elevance Health. Approach 2: Elevance Health Price vs Earnings For a profitable company like Elevance Health, the P/E ratio is a straightforward way to link what you pay for each share to the earnings that back it. It helps you see how many dollars the market is currently willing to pay for each dollar of profit. What counts as a “normal” P/E depends heavily on how the market views a company’s growth potential and risk. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher uncertainty usually points to a lower P/E. Elevance Health currently trades on a P/E of 12.10x. That sits well below the Healthcare industry average of about 22.51x and also below the peer group average of 22.62x. Simply Wall St’s Fair Ratio for Elevance Health is 29.21x, which is its own estimate of a suitable P/E given factors like earnings growth, profit margins, industry, market cap and company specific risks. This Fair Ratio is more tailored than a simple comparison with industry or peers because it ties the valuation to Elevance Health’s own characteristics rather than broad averages. With a Fair Ratio of 29.21x versus the current 12.10x, the shares screen as undervalued on this metric. Result: UNDERVALUED NYSE:ELV P/E Ratio as at Apr 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies. Upgrade Your Decision Making: Choose your Elevance Health Narrative Earlier it was mentioned that there is an even better way to understand valuation. This is where Narratives come in, giving you a clear story behind the numbers by tying your view on Elevance Health’s future revenue, earnings and margins to a specific Fair Value that you can compare with the current price. A Narrative on Simply Wall St’s Community page is essentially your thesis written in numbers and words. It links what you think is happening with Elevance Health’s business to a forecast and then to a valuation that updates automatically when new news, guidance or earnings are added to the platform. For Elevance Health right now, one investor might align with the higher Fair Value view at about US$442.18 per share, reflecting assumptions closer to the more optimistic analyst cohort. Another might lean toward the lower Fair Value near US$332, which reflects a more cautious stance. Narratives make it easy for you to see these different stories side by side and decide how your own view compares. Do you think there's more to the story for Elevance Health? Head over to our Community to see what others are saying! NYSE:ELV 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Elevance Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626922175","isCrawlerRequest":true}